Khurem Farooq, Verdiva Bio CEO
Aiolos team reunites with $411M for new biotech with obesity drugs from China
There’s a shopping bonanza for new obesity medicines going on among a marquee cohort of biopharma investors who are in-licensing treatment candidates from Chinese and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.